Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

73.62
-0.4900-0.66%
Post-market: 73.620.00000.00%17:36 EDT
Volume:1.44M
Turnover:106.87M
Market Cap:10.23B
PE:-10.25
High:75.10
Open:73.23
Low:73.13
Close:74.11
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:0.94
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-59.00
PE(LYR):-11.26

Loading ...

Cytokinetics Initiated at Buy by Citigroup

Dow Jones
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

Cytokinetics initiated with a Buy, named a top pick at Citi

TIPRANKS
·
May 19

Cytokinetics grants 20,807 stock options at USD 75.85 under inducement plan

Reuters
·
May 19

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
May 19

Morgan Stanley Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
May 18

Major Insider Move Rocks Cytokinetics Investors

TIPRANKS
·
May 15

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

GlobeNewswire
·
May 14

Cytokinetics management participates in RBC Capital Markets Global Healthcare Conference fireside chat

Reuters
·
May 13

Cytokinetics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 12

U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis

Reuters
·
May 12

Cytokinetics says aficamten beats metoprolol in Phase 3 MAPLE-HCM analysis

Reuters
·
May 11

Cytokinetics Announces New Data Related to Myqorzo® (Aficamten) at Esc Heart Failure 2026

THOMSON REUTERS
·
May 11

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

GlobeNewswire
·
May 11

Cytokinetics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
May 11

Cytokinetics Raises $760 Million in Stock Offering

TIPRANKS
·
May 09

Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says

MT Newswires Live
·
May 09

Stock Track | Cytokinetics Soars 5.64% Intraday on Successful $805 Million Public Offering and Positive Clinical Trial Data

Stock Track
·
May 09

Cytokinetics prices 11,338,028-share follow-on offering at $71, raising $805 million

Reuters
·
May 08